Title: Post-Marketing Surveillance of the Safety Profile of Infliximab in 5,000 Japanese Patients with Rheumatoid Arthritis

*: Member of the Committee on Post-Marketing Surveillance of Japan College of Rheumatology 1) Tsutomu Takeuchi MD; Division of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan. 2) Yoshihiko Tatsuki; Pharmaceuticals Sales & Marketing Headquarters, Yoshihide Nogami; Compliance & Assurance Headquarters, Tanabe Seiyaku Co., LTD, Osaka, Japan. 3) Naoki Ishiguro MD; Department of Orthopaedic Surgery, Nagoya University School of Medicine, Aichi, Japan. 4) Yoshiya Tanaka MD; The First Department of Internal Medicine, University of Occupational & Environmental Health, School of Medicine, Fukuoka, Japan. 5) Hisashi Yamanaka MD; Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan 6) Masayoshi Harigai MD; Department of Pharmacovigilance and Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan. 7) Junnosuke Ryu MD; Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan. 8) Kazuhiko Inoue MD; Department of Orthopaedic Surgery, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan. 9) Hirobumi Kondo MD; Kitasato Institute Medical Center Hospital, Saitama, Japan. 10) Shigeko Inokuma MD; Department of Allergy and Immunological Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan. 11) Naoyuki Kamatani MD; Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan. 12) Takahiro Ochi MD; National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan. 13) Takao Koike MD; Department of Medicine II, Hokkaido University Graduate School of Medicine, Hokkaido, Japan